ApoGen Biotechnologies is involved in the development of a new class of therapies, self-described.

ApoGen Biotechnologies, Inc.

Viewport Meta

IPhone / Mobile Compatible

SSL by Default

Google Maps

WordPress

Cloudflare CDN

Cloudflare Hosting

Cloudflare

Wordpress Plugins

Cloudflare Network Error Logging

Business Management

Laszlo Radvanyi

Engineering

Sabine Ellwanger

Senior Scientist

Ming Li

Keno Gutierrez

John Santini

Reuben Harris

Apogen Biotechnologies

Stephen Gwaltney

Vice President, Chemistry

Western US Companies With Fewer Than 10 Employees (Top 10K)

Biotechnology Early Stage Companies With Fewer Than 50 Employees

Washington Companies With Fewer Than 100 Employees (Top 10K)

United States Early Stage Companies With Less Than $1M in Revenue

ApoGen Biotechnologies, Inc. is focused on the development of new class of therapeutics targeting drivers of cancer genomic mutation.As the arsenal of available cancer therapies has grown and evolved from cytotoxic chemotherapy to targeted therapy to immunotherapy, one fact has unfortunately remained constant nearly all cancer drug therapies eventually fail due to the development of drug resistance. Mutation of cellular DNA is central to the formation of cancer, and chronic mutation of the cancer genome is a primary cause of cancer evolution and drug resistance, resulting in ineffective therapy, cancer recurrence and metastasis, and decreased overall survival.

M Ventures

Series A - ApoGen Biotechnologies

Accelerator Corp.

Pre Seed Round - ApoGen Biotechnologies

Computer and Software Services and Scientific Services

Seattle

Washington

United States

North America

ApoGen Biotechnologies

MyPathway Human Epidermal Growth Factor Receptor 2 ...

These inhibitors are designed to target and inhibit the activity of APOBEC3B, a DNA cytosine deaminase that contributes to DNA mutation in cancer, aiming to slow or stop cancer genome mutation and the development of drug resistance.

HTML5

Google Compute Engine

Apache Server

Microsoft Outlook

Vimeo

GoDaddy Premium DNS

Office 365

Bootstrap

Google Fonts

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Nov 23, 2024 9:09 AM	3f17c189
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 23, 2024 9:09 AM	fdc71bdc
crunchbase trigger	general	Nov 23, 2024 9:09 AM	6087909d
crunchbase profile	general	Nov 24, 2024 4:23 AM	17388b61
li profile	general	Nov 23, 2024 9:09 AM	a635d79b
translate crunchbase fundingrounds	general	Nov 24, 2024 5:00 AM	adf49e02
peers	general	Nov 23, 2024 9:09 AM	ae8b527e
news basic	general	Nov 23, 2024 9:09 AM	389e898d
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

APOG

COM:APOGENBIOTECH

ApoGen Biotechnologies, Inc.